3H-咪唑并[4,5-C]吡啶-6-甲酸甲酯 | 82523-07-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3H-咪唑并[4,5-C]吡啶-6-甲酸甲酯
• 英文名称: 3H-imidazo[4,5-c]pyridine-6-carboxylic acid methyl ester
• 英文别名: Methyl 3H-imidazo[4,5-C]pyridine-6-carboxylate
• CAS: 82523-07-7
• 化学式: C₈H₇N₃O₂
• 分子量: 177.162
• InChiKey: PTZVKSLCCQTAJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H320,H335
• 储存条件：
  存储条件：室温下，应保持干燥并密封保存。

反应信息

• 作为反应物：
  描述：

  3H-咪唑并[4,5-C]吡啶-6-甲酸甲酯 在 palladium on activated charcoal 、 水 、 氢气 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 sodium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 40.5h， 生成 3H-imidazo[4,5-c]pyridine-6-carboxamido-Orn(Boc)
  参考文献：
  名称：

  极性氨基酸苄酯修饰的菠菜素、其合成、活性 评价及应用

  摘要：

  极性氨基酸苄酯修饰的菠菜素、其合成、活性评价及应用，本发明公开了下式的3H‑咪唑并[4,5‑c]吡啶‑6‑甲酰‑[N‑(Cl‑CH2C＝NH)‑Orn]‑AA‑OBzl(式中AA选自L‑Met,L‑Asn,L‑Arg(NO2),L‑Ser,L‑Tyr,L‑Thr,L‑Glu(OBzl),L‑Asp(OBzl)和L‑Gln残基),公开了它们的制备方法,公开了它们对肿瘤生长的抑制作用，公开了它们的抗炎活性。因而本发明公开了它们在制备抗肿瘤抗药物及抗炎药物中的应用。

  公开号：

  CN108976225B
• 作为产物：
  描述：

  L-组氨酸盐酸盐 在 盐酸 、 selenium(IV) oxide 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 4.25h， 生成 3H-咪唑并[4,5-C]吡啶-6-甲酸甲酯
  参考文献：
  名称：

  Biomimetic approach to potential benzodiazepine receptor agonists and antagonists

  摘要：

  Several beta-carbolines, isoquinolines, imidazopyridines , and canthin -6-ones prepared in biomimetic fashion were tested for their ability to bind to the benzodiazepine receptor. Methyl isoquinoline-3-carboxylate, methyl 6,7- dimethoxyisoquinoline -3-carboxylate (3b) 1-phenyl-3- carbomethoxyimidazopyridine , (6B,) and canthin -6- one ( 13a ) bound with moderate affinities, while 2- carbomethoxycanthin -6- one ( 13b ) bound to benzodiazepine receptors with an affinity comparable to several pharmacologically active benzodiazepines. The potency of 13b suggests that the benzodiazepine receptor(s) can tolerate substitution at positions 1 and 9 of a beta-carboline without loss of activity if the substituents are trigonal and maintain a planar topography. Moreover, displacement of the carbonyl group by two atoms from the aromatic ring (C) of the beta-carboline skeleton caused a marked decrease in binding to the benzodiazepine receptor. This observation supports the hypothesis that maximum binding affinity of beta-carbolines is achieved when the carbonyl group at position 3 is attached directly to the aromatic pyridine ring.

  DOI：

  10.1021/jm00371a002

文献信息

• Thrombin inhibitors
  申请人：Merck & Co., Inc.

  公开号：US06610692B1

  公开（公告）日：2003-08-26

  Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein b is NY or O; c is CY2 or N; d is CY3 or N; e is CY4 or N; f is CY5 or N; g is CY6 or N; Y4, Y5, and Y6 are independently hydrogen, C1-4 alkyl, or halogen; Y1 and Y2 are independently hydrogen, C1-4 alkyl, C3-7 cycloalkyl, halogen, NH2, OH or C1-4 alkoxy, and Y3 is hydrogen, C1-4 alkyl, C3-7 cycloalkyl, halogen, —CN, NH2, OH or C1-4 alkoxy; A is and W, W1, R1, R3, R4, R5, X and Z are defined in the specification.

  发明的化合物在抑制凝血酶和相关血栓闭塞方面具有以下结构：或其药学上可接受的盐，其中b为NY或O；c为CY2或N；d为CY3或N；e为CY4或N；f为CY5或N；g为CY6或N；Y4、Y5和Y6独立地为氢、C1-4烷基或卤素；Y1和Y2独立地为氢、C1-4烷基、C3-7环烷基、卤素、NH2、OH或C1-4烷氧基，Y3为氢、C1-4烷基、C3-7环烷基、卤素、—CN、NH2、OH或C1-4烷氧基；A为，并且W、W1、R1、R3、R4、R5、X和Z在规范中有定义。
• [EN] BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLE BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE L'ECTONUCLÉOTIDE PYROPHOSPHATASE/PHOSPHODIESTÉRASE 1
  申请人：RIBOSCIENCE LLC

  公开号：WO2020210649A1

  公开（公告）日：2020-10-15

  The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本公开提供了一些抑制细胞外核苷酸焦磷酸酶/磷酸二酯酶1（ENPP1）酶活性的双环杂环芳基化合物，因此对于治疗至少部分受ENPP1调节的疾病和病况是有用的。在某些实施例中，双环杂环芳基化合物包括式（I）中的化合物。本文还提供了含有这类化合物的药物组合物以及制备这类化合物的方法。
• 非极性氨基酸苄酯修饰的菠菜素、其合成、活 性评价及应用
  申请人：首都医科大学

  公开号：CN108976226B

  公开（公告）日：2021-03-30

  非极性氨基酸苄酯修饰的菠菜素、其合成、活性评价及应用，本发明公开了下式的3H‑咪唑并[4,5‑c]吡啶‑6‑甲酰‑[N‑(Cl‑CH2C＝NH)‑Orn]‑AA‑OBzl(式中AA选自L‑Pro,Gly,L‑Ala,L‑Phe,L‑Ile,L‑Leu,L‑Val和L‑Trp),公开了它们的制备方法,公开了它们对肿瘤生长的抑制作用，公开了它们的抗炎活性。因而本发明公开了它们在制备抗肿瘤抗药物及抗炎药物中的应用。
• NOVEL HETEROCYCLIC COMPOUND
  申请人：DAEWOONG PHARMACEUTICAL CO., LTD.

  公开号：US20170088551A1

  公开（公告）日：2017-03-30

  The present invention relates to a compound represented by chemical formula 1, which can be used for the prevention and treatment of diseases caused by abnormality in a prolyl-tRNA synthetase (PRS) activity, or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition comprising the same.

  本发明涉及一种化学式1所代表的化合物，可用于预防和治疗由脯氨酰-tRNA合成酶（PRS）活性异常引起的疾病，或其药用盐，以及制备该化合物的方法和包含该化合物的药物组合物。
• [EN] NOVEL OXIME DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] NOUVEAUX DÉRIVÉS D'OXIMES ET LEUR UTILISATION COMME MODULATEURS ALLOSTÉRIQUES DE RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE
  申请人：DOMAIN THERAPEUTICS

  公开号：WO2011051478A1

  公开（公告）日：2011-05-05

  The present invention provides new oxime derivatives of the general formula (I), pharmaceutical compositions containing them and their use for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. This invention further provides new oxime derivatives of the general formula (I) consisting of modulators of nervous system receptors sensitive to glutamate, which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. In particular embodiments, the new oxime derivatives of the invention are modulators of metabotropic glutamate receptors (mGluRs). The invention further provides positive allosteric modulators of mGluRs and more specifically positive alSosteric modulators of mGiuR4.

  本发明提供了一般式（I）的新羟肟衍生物，包含它们的药物组合物以及它们用于治疗和/或预防与改变的谷氨酸信号和/或功能有关的疾病，和/或在哺乳动物中改变谷氨酸水平或信号会影响的疾病。本发明进一步提供了一般式（I）的新羟肟衍生物，它们是对谷氨酸敏感的神经系统受体的调节剂，因此特别适用于治疗和/或预防急性和慢性神经和/或精神障碍。在特定实施例中，本发明的新羟肟衍生物是代谢型谷氨酸受体（mGluRs）的调节剂。本发明还提供了mGluRs的正向变构调节剂，更具体地说是mGluR4的正向变构调节剂。